Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Double homeobox A pseudogene 11 (DUXAP11) is annotated as a pseudogene and presumed non-coding RNA, but there is currently no primary literature or curated data describing its molecular function, biology, or clinical significance. No evidence identifies DUXAP11 as a therapeutic target or biomarker, and it should not be confused with functionally characterized loci such as DUX4 or the related pseudogene DUXAP10, which have established roles in cancer. Additionally, DUXAP11 is sometimes misreported in literature databases due to the similarity of pseudogene names; no current data link DUXAP11 to any disease process or druggability. Key notes: - DUXAP11 is a pseudogene; its transcript has not been functionally characterized, and there are no known molecular or pharmacological roles. - Do not confuse DUXAP11 with DUXAP10, which is a lncRNA pseudogene under active research in oncology. - No clinical, therapeutic, or biomarker use of DUXAP11 has been established to date. - This entry is likely to have incomplete or missing information for most structured fields due to its uncharacterized status.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Double homeobox A pseudogene 11 (DUXAP11).